Regor Pharmaceuticals USA has finalized a purchase agreement through which Genentech, a subsidiary of the Roche Group, will acquire a portfolio of advanced CDK inhibitors from Regor for the treatment of breast cancer. This agreement includes an upfront cash payment of $850 million to Regor, with the potential for additional financial incentives. Under this agreement, Genentech will take on the responsibilities of clinical development, manufacturing, and commercialization.
Regor Pharmaceuticals USA is an affiliate of the Regor Therapeutics Group, a clinical-stage biotechnology company dedicated to developing innovative, clinically differentiated therapies aimed at addressing significant unmet needs in oncology, metabolism, and autoimmunity.
